Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Q3 2019 Earnings Conference Call - Final Transcript
Nov 06, 2019 • 05:00 pm ET
Greetings and welcome to the Bellicum Pharmaceuticals Third Quarter 2019 Financial Results Conference Call. [Operator Instructions]
I would now like to turn the conference over to your host Mr. Robert Uhl, Westwicke IR. Please go ahead, sir.
Thank you, Jerry. Good afternoon, everyone, and thank you for joining us. With me today on the call is Rick Fair, Bellicum's President and Chief Executive Officer; and Atabak Mokari, Chief Financial Officer. Later, during the Q&A session, Aaron Foster, Head of Research, will also be available.
Earlier this afternoon, Bellicum released financial results for the third quarter ended September 30th, 2019. If you have not received this release, or if you would like to be added to the distribution list, you can do so on the Investor Relations page of the Company's website.
As a reminder, today's conference call will include forward-looking statements made under the Private Securities Litigation Reform Act of 1995, including statements regarding our research and development plans, clinical trials, plans regarding regulatory filings, review and approval of our product candidates, commercialization expectations and our financial outlook.
These forward-looking statements involve a number of risks and uncertainties and reflect our opinions only as of the date of this call. We undertake no obligation to revise or publicly release the results of any revision of these forward-looking statements in light of new information or future events. Actual results may differ from those indicated by these forward-looking statements due to numerous factors, including those discussed in the Risk Factors section of our Form 10-Q for the quarter ended September 30th, 2019 filed with the Securities and Exchange Commission.
And now, I will turn the call over to Rick Fair, Bellicum's President and CEO.
Thanks, Robert. Good afternoon, everyone. Thanks for joining us. On our call today, I'll provide an update regarding the progress we've made to focus the company exclusively on our GoCAR pipeline, which was the basis for our recent financing. I'll also provide an update on our efforts to identify partners for RIVO-CEL and our manufacturing facility.
Let me begin by highlighting our GoCAR platform driven by our inducible MyD88 and CD40 activation switch, what we call iMC. As a next-generation CAR platform, we believe iMC may improve upon current generation products in several ways. First, costimulatory molecules MyD88 and CD40 enhanced cell proliferation and persistence. Second, our preclinical research suggests iMC may modulate the tumor microenvironment by overriding common inhibitory pathways such as PD-1, PGE2 and TGF-beta. Third, we believe iMC may enhance host immune activity to complement GoCAR efficacy by inducing pro-inflammatory cytokines and chemokines. And finally, because iMC is driven by our switch technology, we can control the timing and frequency of cell activation through the infusion of our small molecule rimiducid.
In our dual switch product candidates, we improved controllability further by incorporating our CaspaCIDe safety switch which can be used to manage acute toxicities quickly. These control features may enable clinicians to better manage the benefit risk profile of treatment.
With that background on the